Physician profile
Abel E Gonzalez
NPI 1568711448
$21,443.86
in general payments reported to CMS, 2019-2025
62 companies · $2,834 in 2025
The $2,834 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,103 · 2020: $2,581 · 2021: $2,752 · 2022: $3,014 · 2023: $3,542 · 2024: $3,618 · 2025: $2,834.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,927 · Education: $67.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,926.74 |
| Education | $67.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,668.05 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,681.76 | 2019-2025 | |
| Lilly USA, LLC | $1,662.49 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,298.10 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $1,149.03 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $1,117.78 | 2019-2025 | Repatha, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $900.08 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Pfizer INC. | $842.29 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $826.53 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $658.72 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $648.17 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $606.28 | 2019-2024 | Cycloset, Xifaxan, Trulance |
| Amarin Pharma, INC. | $578.61 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $457.63 | 2019-2025 | Zoryve, Seglentis, Livalo |
| Ardelyx, INC. | $424.30 | 2023-2025 | Ibsrela |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $409.09 | 2024-2025 | Korlym |
| Dexcom, INC. | $386.97 | 2021-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $381.73 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $321.90 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $282.61 | 2022-2024 | Quviviq |
| Astellas Pharma US INC | $230.27 | 2022-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $224.62 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Azurity Pharmaceuticals, INC. | $204.46 | 2023-2024 | Edarbi, Edarbi, Horizant |
| Xeris Pharmaceuticals, INC. | $197.79 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Daiichi Sankyo INC. | $184.77 | 2021-2023 | Injectafer |
| Scilex Pharmaceuticals INC. | $167.15 | 2020-2022 | |
| Allergan, INC. | $137.37 | 2019-2021 | |
| Hikma Pharmaceuticals USA | $114.81 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $103.25 | 2019-2020 | |
| Abbott Laboratories | $101.69 | 2021-2025 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $93.57 | 2022-2024 | Eliquis |
| Intra-Sana Laboratories | $91.03 | 2023 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Horizon Therapeutics Plc | $82.35 | 2020-2022 | |
| Gilead Sciences, INC. | $79.23 | 2019-2025 | Yeztugo |
| Biohaven Pharmaceutical Holding Company Ltd. | $70.80 | 2022 | |
| Ucb, INC. | $70.55 | 2024-2025 | Bimzelx, Cimzia |
| Nestle Healthcare Nutrition INC. | $70.40 | 2020-2021 | |
| Antares Pharma, INC. | $70.30 | 2024 | Xyosted |
| Lundbeck LLC | $68.27 | 2024-2025 | Rexulti |
| Esperion Therapeutics, INC. | $62.95 | 2023-2024 | Nexletol |
| Almatica Pharma LLC | $62.27 | 2023-2024 | Loreev Xr, Gralise |
| Takeda Pharmaceuticals U.S.A., INC. | $61.34 | 2019-2023 | Vpriv |
| Otsuka America Pharmaceutical, INC. | $56.11 | 2024-2025 | Rexulti |
| Axsome Therapeutics, INC. | $48.57 | 2025 | Auvelity |
| Sanofi Pasteur INC. | $47.63 | 2023 | |
| Eisai INC. | $43.30 | 2019-2021 | |
| Genentech USA, INC. | $40.35 | 2019 | |
| Insulet Corporation | $39.91 | 2023 | Omnipod |
| Nabriva Therapeutics, Plc | $37.61 | 2020-2021 | |
| Aimmune Therapeutics, INC. | $34.05 | 2024 | |
| Boston Scientific Corporation | $31.57 | 2025 | Watchman Access System |
| Phathom Pharmaceuticals, INC. | $31.09 | 2024-2025 | Voquezna |
| Arbor Pharmaceuticals, INC. | $29.99 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $25.58 | 2021 | |
| Phadia US INC. | $19.25 | 2024 | Immunocap |
| Medtronic, INC. | $18.57 | 2023 | Intellis Adaptivestim |
| Currax Pharmaceuticals LLC | $17.17 | 2024 | Contrave |
| Amphastar Pharmaceuticals, INC. | $16.88 | 2025 | |
| Eyevance Pharmaceuticals LLC | $15.20 | 2021 | |
| Vanda Pharmaceuticals INC. | $15.09 | 2024 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $12.79 | 2021 | |
| Metuchen Pharmaceuticals | $11.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abel Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.